$AXSM News
Last published 3d ago
- 3d agoAXSMGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - AXSOME THERAPEUTICS INCEarnings Call TranscriptsPerfect, okay. All right, I think we're live now. Good morning, everyone. Welcome to Google IAM Third Annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the biotech analysts here at the firm. My ple
- 3d agoAXSMGuggenheim 3rd Annual Healthcare Innovation Conference - AXSOME THERAPEUTICS INCEarnings Call TranscriptsPerfect, okay. All right, I think we're live now. Good morning, everyone. Welcome to Google IAM Third Annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the biotech analysts here at the firm. My ple
- 1w agoAXSMAxsome Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it
- 1w agoAXSMAXSOME Third Quarter 2026 Financial Results - AXSOME THERAPEUTICS INCEarnings Call TranscriptsGood morning, and welcome to the Axiom Therapeutics Third Quarter 2026 Earnings Conference Call. My name is Kevin. I'll be your operator for today's call. At this time, all participants are in listening-only mode. Later,
- 1w agoAXSMAxsome Third Quarter 2026 Financial Results - AXSOME THERAPEUTICS INCEarnings Call TranscriptsGood morning, and welcome to the Axiom Therapeutics Third Quarter 2026 Earnings Conference Call. My name is Kevin. I'll be your operator for today's call. At this time, all participants are in listening-only mode. Later,
- 1w agoAXSMAxsome Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
- 1w agoAXSMAxsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireTotal 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI® 3Q 2026 net product
- 1mo agoAXSMAxsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2GlobeNewswireNEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will
- 1mo agoAXSMAxsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s DayGlobeNewswireThe Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported
- 1mo agoAXSMAxsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026GlobeNewswireNEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced
- 1mo agoAXSMMorgan Stanley 24th Annual Global Healthcare Conference - AXSOME THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, everyone. I'm Sean Laman, head of US Mid-Cap Biotech Equity Research here at Morgan Stanley. Welcome to our Global Healthcare Conference. For important disclosures before we commence, please see the Morga
- 1mo agoAXSMAxsome Therapeutics, Inc. - 1773719 - AXSOME THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, everyone. I'm Sean Laman, head of US Mid-Cap Biotech Equity Research here at Morgan Stanley. Welcome to our Global Healthcare Conference. For important disclosures before we commence, please see the Morga
- 2mo agoAXSMWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - AXSOME THERAPEUTICS INCEarnings Call TranscriptsOkay. We'll go ahead and get started with the next one. I'm Ben Burnett, Biotech Analyst at Wells Fargo. Pleased to be here with the Axome Management Team. We have Nick Pizzi, CFO, and then to his right we have Mark Jaco
- 2mo agoAXSMWells Fargo 21st Annual Healthcare Conference - AXSOME THERAPEUTICS INCEarnings Call TranscriptsOkay. We'll go ahead and get started with the next one. I'm Ben Burnett, Biotech Analyst at Wells Fargo. Pleased to be here with the Axome Management Team. We have Nick Pizzi, CFO, and then to his right we have Mark Jaco
- 2mo agoAXSMAxsome Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it
- 2mo agoAXSMAxsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking CessationGlobeNewswireNEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the
- 3mo agoAXSMAxsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireTotal 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI® 2Q 2026 net product
- 4mo agoAXSMAxsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in NarcolepsyGlobeNewswireFDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous
- 4mo agoAXSMAxsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10GlobeNewswireNEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will
- 4mo agoAXSMAxsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)GlobeNewswireThe FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company
- 4mo agoAXSMAxsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)GlobeNewswireNEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the
- 4mo agoAXSMAxsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness MonthGlobeNewswireNEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is
- 5mo agoAXSMAxsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026GlobeNewswireNEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced
- 5mo agoAXSMAxsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific MeetingGlobeNewswireNEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced
- 5mo agoAXSMAxsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent LitigationGlobeNewswireNEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced
- 5mo agoAXSMAxsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness MonthGlobeNewswireNEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today highlighted its
- 5mo agoAXSMAxsome Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will
- 5mo agoAXSMAxsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual MeetingGlobeNewswireNEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced
- 6mo agoAXSMAxsome Therapeutics Recognizes Mental Health MonthGlobeNewswireNEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced its support
- 6mo agoAXSMAxsome Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will
- 6mo agoAXSMAxsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireTotal 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth AUVELITY® 1Q 2026 net product sales of $153.2 million, representing 59% year-over-year growth SUNOSI® 1Q 2026 net
- 6mo agoAXSMAxsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought LeaderGlobeNewswireNEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor
- 6mo agoAXSMAxsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer's DiseaseGlobeNewswireAUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of AUVELITY in
- 7mo agoAXSMAxsome Therapeutics to Report First Quarter 2026 Financial Results on May 4GlobeNewswireNEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will
- 7mo agoAXSMAxsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric ConditionsGlobeNewswireAxsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome's industry-leading CNS portfolio with a novel mechanism for
- 8mo agoHELPCMPSRLMDANRO+1Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS DisordersPR NewswireUSA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that ...
- 8mo agoAXSMAxsome Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it
- 8mo agoAXSMAxsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness SymptomsGlobeNewswireNEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the
- 8mo agoAXSMAxsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireTotal 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q and full year 2025 net product sales of $155.1 million
- 8mo agoAXSMAxsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireNEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it
- 8mo agoAXSMAxsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.GlobeNewswireNEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced
- 9mo agoAXSMAxsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23GlobeNewswireNEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will
- 10mo agoAXSMAxsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of FibromyalgiaGlobeNewswireNEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first
- 10mo agoAXSMAxsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product RevenueGlobeNewswireTotal preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual growth, respectively AUVELITY® preliminary 4Q and full year 2025 net
- 10mo agoAXSMAxsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer's Disease AgitationGlobeNewswireFDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading
- 10mo agoAXSMAxsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA SubmissionGlobeNewswireNew Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of
- 11mo agoAXSMAxsome Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it
- 1y agoAXSMApproval of Auvelity, Nda #215430 (Labeling)FDA Approved DrugsApproval Date: 11/05/2025; Drug Name: Auvelity, Nda #215430; Active Ingredients: BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE; Company: Axsome; Submission Status: Approval; Submission Classification: Labeling; Application Number: 215430
- 1y agoAXSMAxsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireTotal 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growth AUVELITY® 3Q 2025 net product sales of $136.1 million, representing 69% year-over-year growth SUNOSI® 3Q 2025 net
- 1y agoAXSMAxsome Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it